AR113805A1 - Composiciones y métodos para tratar cáncer hepático - Google Patents

Composiciones y métodos para tratar cáncer hepático

Info

Publication number
AR113805A1
AR113805A1 ARP180103133A ARP180103133A AR113805A1 AR 113805 A1 AR113805 A1 AR 113805A1 AR P180103133 A ARP180103133 A AR P180103133A AR P180103133 A ARP180103133 A AR P180103133A AR 113805 A1 AR113805 A1 AR 113805A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
liver cancer
treat liver
pembrolizumab
Prior art date
Application number
ARP180103133A
Other languages
English (en)
Spanish (es)
Inventor
Michael Kevin Wolf
Swaminathan Murugappan
Jennifer Lorraine Gansert
Original Assignee
Merck Sharp & Dohme
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Amgen Inc filed Critical Merck Sharp & Dohme
Publication of AR113805A1 publication Critical patent/AR113805A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ARP180103133A 2017-10-27 2018-10-26 Composiciones y métodos para tratar cáncer hepático AR113805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762578071P 2017-10-27 2017-10-27

Publications (1)

Publication Number Publication Date
AR113805A1 true AR113805A1 (es) 2020-06-10

Family

ID=64453576

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103133A AR113805A1 (es) 2017-10-27 2018-10-26 Composiciones y métodos para tratar cáncer hepático

Country Status (13)

Country Link
US (1) US20200353022A1 (https=)
EP (1) EP3700544A1 (https=)
JP (1) JP2021501150A (https=)
KR (1) KR20200078483A (https=)
CN (1) CN111278448A (https=)
AR (1) AR113805A1 (https=)
AU (1) AU2018355519A1 (https=)
BR (1) BR112020007494A2 (https=)
CA (1) CA3075294A1 (https=)
MX (1) MX2020003388A (https=)
SG (1) SG11202002123XA (https=)
TW (1) TWI817958B (https=)
WO (1) WO2019084418A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US12310999B2 (en) * 2017-04-28 2025-05-27 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
CN114191547A (zh) * 2021-12-23 2022-03-18 中山大学 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用
WO2025085538A1 (en) * 2023-10-17 2025-04-24 Lanier Biotherapeutics, Inc. Alarmin binding molecules and treatment of cancer
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
ES2676205T3 (es) 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
JP6457940B2 (ja) 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
DK3169341T3 (da) * 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
AU2015289081B2 (en) * 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
PL3426271T3 (pl) * 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
WO2018111902A1 (en) * 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US12310999B2 (en) * 2017-04-28 2025-05-27 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics

Also Published As

Publication number Publication date
SG11202002123XA (en) 2020-04-29
CN111278448A (zh) 2020-06-12
TW201922273A (zh) 2019-06-16
WO2019084418A1 (en) 2019-05-02
RU2020111709A (ru) 2021-11-29
KR20200078483A (ko) 2020-07-01
BR112020007494A2 (pt) 2020-11-03
RU2020111709A3 (https=) 2022-04-26
US20200353022A1 (en) 2020-11-12
MX2020003388A (es) 2020-08-03
JP2021501150A (ja) 2021-01-14
AU2018355519A1 (en) 2020-03-26
EP3700544A1 (en) 2020-09-02
CA3075294A1 (en) 2019-05-02
TWI817958B (zh) 2023-10-11

Similar Documents

Publication Publication Date Title
MX2018013413A (es) Compuestos inhibidores de egfr.
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
AR113805A1 (es) Composiciones y métodos para tratar cáncer hepático
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
PT3986897T (pt) Inibidor do egfr para o tratamento do cancro
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
AU2017348322A8 (en) Compositions and methods for treating EZH2-mediated cancer
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
MX2019007471A (es) Composiciones y métodos para inhibir la actividad de la arginasa.
CO2017012342A2 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit)
BR112017023821A2 (pt) moduladores de k-ras
IL268676A (en) Inhibition of smarca2 for treatment of cancer
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2015005536A (es) Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa.
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
CL2025000404A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
MX2020006297A (es) Variantes de cd19.
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
MX382996B (es) Inhibidores de pcna
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
PH12017501879A1 (en) Methods for treating cancer
JOP20190190B1 (ar) معالجة سرطان
MX2017010002A (es) Terapias de combinacion.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure